Nautilus Biotechnology, Inc.
NASDAQ:NAUTBiotechnology
Healthcare
$2.43 +2.06%
+$0.05 today
- Market cap
- $309.51M
- Beta
- 0.75
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.45
52W Low $0.62High $4.31
Volume 4.55M
Average 0.40M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$50.70M
FY 2025 · Annual
Investing Cash Flow
$35.22M
FY 2025 · Annual
-46.8% YoYFinancing Cash Flow
$214,000.00
FY 2025 · Annual
-81.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (50.32M) | (57.92M) | (63.68M) | (70.78M) | (59M) |
| Depreciation & Amortization | 2.84M | 3.42M | 5.71M | 6.35M | 6.47M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.93M | 10.38M | 12.14M | 12.7M | 6.84M |
| Change in Working Capital | (22K) | (788K) | (3.22M) | (5.46M) | (3.58M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.26M | (561K) | 393K | (578K) | (69K) |
| Other Working Capital | (1.28M) | (227K) | (3.61M) | (4.88M) | (3.52M) |
| Other Non-Cash Items | 320K | (890K) | (2.66M) | (1.96M) | (1.42M) |
| Operating Cash Flow | (39.24M) | (45.81M) | (51.71M) | (59.15M) | (50.7M) |
| Capital Expenditures | (2.27M) | (2.32M) | (2.44M) | (2.12M) | (1.28M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (221.8M) | (186.59M) | (112.89M) | (86.28M) | (72.49M) |
| Sales of Investments | 85.1M | 163.18M | 71.6M | 155.41M | 108.99M |
| Other Investing Activities | 0 | 0 | 0 | (760K) | 0 |
| Investing Cash Flow | (138.96M) | (25.74M) | (43.74M) | 66.25M | 35.22M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | (7.96M) | 562K | 368K | 1.14M | 214K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 335.41M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 327.45M | 562K | 368K | 1.14M | 214K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 149.24M | (70.98M) | (95.08M) | 8.25M | (15.26M) |
| Free Cash Flow | (41.51M) | (48.13M) | (54.15M) | (61.27M) | (51.97M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$59.0M
+ D&A$6.5M
+ Stock-Based Comp$6.8M
+ Deferred Tax$0
- Working Capital-$3.6M
- Other Non-Cash-$1.4M
= Operating Cash Flow-$50.7M
- Capex-$1.3M
= Free Cash Flow-$52.0M
Analysis
FY2025 free cash flow is -$52.0M. FCF conversion is 88.1% of net income. Operating cash flow was -$50.7M, with capex of -$1.3M. The largest bridge item is Stock-Based Comp at $6.8M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Nov 3, 2026 | |
| 10-Q | Quarterly report | Oct 27, 2026 | |
| 8-K | Current report | Oct 27, 2026 | |
| EFFECT | EFFECT filing | Sep 18, 2026 | |
| 424B5 | 424B5 filing | Sep 18, 2026 |
Does NAUT generate free cash flow?
Nautilus Biotechnology, Inc. (NAUT) generated -$51.97M of free cash flow in fiscal 2025.
How much operating cash flow does NAUT produce?
Operating cash flow was -$50.70M, before capital expenditures of $1.28M.
Continue the stock analysis
Jump to another research area for this company.